Popular Gemcitabine News and Current Events | Page 2

Popular Gemcitabine News and Current Events, Gemcitabine News Articles.
Sort By: Most Relevant | Most Recent
Page 2 of 6 | 208 Results
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results. (2004-06-05)

New drug extends lung cancer survival 22 percent, UC Davis Cancer Center researchers report
Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolonged survival in patients with advanced non-small cell lung cancer. Results of the phase II trial, led by UC Davis Cancer Center researchers, were reported today at the annual meeting of the American Society of Clinical Oncology. (2006-06-03)

Immune therapy breaks down wall around pancreatic tumors for chemo to attack
In a new preclinical study in Cancer Discovery, researchers from the Abramson Cancer Center at the University of Pennsylvania have uncovered the poorly understood mechanics of how macrophages can be 're-educated' by an experimental immune therapy to help tear down the scaffolding that surrounds and protects pancreas cancer from chemotherapy. (2016-02-29)

Pancreatic cancer: Less toxic, more enduring drug may improve therapy
A new drug that penetrates the protective barrier around pancreatic cancers and accumulates in malignant cells may improve current chemotherapy, a study in mice suggests. (2019-08-08)

Harnessing anticancer drugs for the future fight against influenza
The researchers at the Institute for Molecular Medicine Finland together with their collaborators developed a new cell screening method that can be used to identify potential anti-influenza drugs. They also identified two novel anti-influenza agents. (2012-09-05)

Scientists show how molecular switch helps pancreatic cancer beat drugs
Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy. (2010-01-28)

A better way to personalize bladder cancer treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. In early proof-of-concept research, the team took bladder tumors from individual patients, identified actionable mutations and grafted the tumors into mice. (2015-08-13)

Switch to metronomic therapy could offer new treatment option for patients with advanced kidney cancer
A new multi-targeted (2010-02-15)

Chemotherapy appears to delay cancer recurrence following surgery for pancreatic cancer
Use of the drug gemcitabine for chemotherapy significantly delays the recurrence of cancer, compared to no chemotherapy, for patients following pancreatic cancer surgery, according to a study in the January 17 issue of JAMA. (2007-01-16)

New biomarker may predict which pancreatic cancer patients respond to CD40 immunotherapy
Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight. (2021-02-04)

'Promising' antibody therapy extends survival in mice with pancreatic cancer
Scientists have found a way to target and knock out a single protein that they have discovered is widely involved in pancreatic cancer cell growth, survival and invasion. (2019-07-31)

Sortilin may hold the key to combat pancreatic cancer more effectively
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States. In a novel study published in The American Journal of Pathology, published by Elsevier, scientists report the discovery of an increased level of the neuroprotein sortilin in pancreatic cancer cells that may open up the way to developing more effective treatment. (2020-08-20)

Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication -- and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed. (2012-03-01)

2013 Gastrointestinal Cancers Symposium reveals new advances for GI cancers
New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held Jan. 24-26, 2013, at the Moscone West Building in San Francisco, Calif. (2013-01-22)

TGen, Scottsdale Healthcare study shows drug combination extends pancreatic cancer patient survival
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. (2013-01-22)

Liverpool to trial new pancreatic cancer therapy
Patients in Liverpool are to trial a new therapy for pancreatic cancer -- a disease which sees most sufferers die within a year of diagnosis. (2007-03-15)

New boost for pancreatic cancer therapy
Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar) -- the chemotherapy drug that is considered standard therapy for the disease. Although gemcitabine is the first line of defense against pancreatic cancer, many cells find ways to evade the treatment. The new research found several compounds that appear to improve the cancer-killing effect of gemcitabine. (2012-04-02)

Combination therapy may enhance gemcitabine activity
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery. (2012-02-28)

Potential cancer therapy may boost immune response
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators. (2020-12-07)

TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO
In association with its 50th anniversary, the American Society of Clinical Oncology (ASCO) has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care. (2014-03-07)

Western University hopes to use artificial intelligence to improve breast cancer patient outcomes
Western University researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy medications used to treat breast cancer -- paclitaxel and gemcitabine. Peter Rogan, Ph.D., and a team of researchers, including Stephanie Dorman, Ph.D., and Katherina Baranova, B.M.Sc., at Western's Schulich School of Medicine & Dentistry, are hoping to one day remove the guesswork from breast cancer treatment with this technique. (2015-09-18)

Patients with EGFR expressing NSCLC benefit most from necitumumab added to chemotherapy
Patients with epidermal growth factor receptor expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference 2016 in Geneva, Switzerland. (2016-04-15)

Simple post-surgery step significantly reduces bladder cancer recurrence
It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true and now a major US study has done the same. Results from the SWOG study will be presented at American Urological Association annual meeting held May 12-16 in Boston. (2017-05-15)

Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Human pancreatic cancer cells dramatically regress when treated with chemotherapy in combination with a synthetic compound that mimics the action of a naturally occurring (2010-03-23)

UCLA scientists develop crystal ball for personalized cancer treatment
UCLA scientists have tested a non-invasive approach that may one day allow doctors to evaluate a tumor's response to a drug before prescribing therapy, enabling physicians to quickly pinpoint the most effective treatment and personalize it to the patient's unique biochemistry. The Proceedings of the National Academy of Sciences publishes the UCLA findings in its Feb. 2 advance online edition. (2009-02-02)

In elderly patients, combination chemotherapy no more effective than individual drugs
For elderly patients with advanced non-small-cell lung cancer (NSCLC), combination chemotherapy with the drugs vinorelbine and gemcitabine appears to be no more effective than either drug alone, but is more toxic, according to a study in the March 5 issue of the Journal of the National Cancer Institute. (2003-03-04)

Fox Chase researchers reveal how pancreatic cancer cells sidestep chemotherapy
Research led by Timothy J. Yen, Ph.D., professor at Fox Chase Cancer Center, reveals that one reason pancreatic cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy. They hijack the vitamin D receptor, normally associated with bone health, and re-purposed it to repair the damage caused by chemotherapy. (2015-01-29)

Glitches in DNA repair genes predict prognosis in pancreatic cancer
Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from the University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. (2009-01-13)

New therapeutic combination to slow resistant sarcomas
Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer. (2014-07-10)

Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients
A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn't live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in JAMA Oncology. (2021-01-21)

Study finds new way to make chemotherapy more effective against pancreatic cancer
Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs. A Mayo Clinic-led study published today opens a promising new front in that battle. (2019-09-18)

Drug with new approach on impeding DNA repair shows promise in first clinical trial
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer. (2020-06-15)

The Lancet Oncology: Price of cancer drugs varies by up to 388% between European countries, Australia, and New Zealand
The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found. (2015-12-03)

Wild berry extract may strengthen effectiveness of pancreatic cancer drug
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology. (2014-09-17)

Adult cancer drugs show promise against an aggressive childhood brain tumor
The quest to improve survival of children with a high-risk brain tumor has led St. Jude Children's Research Hospital investigators to two drugs already used to treat adults with breast, pancreatic, lung and other cancers. The study was published today online ahead of print in the journal Cancer Cell. (2014-03-27)

Disrupting the cellular process that promotes pancreatic cancer's deadly growth
Researchers say they've identified a way to disrupt a process that promotes the growth of pancreatic cancers -- one of the most difficult and deadly cancers to treat. (2020-12-08)

Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective. (2016-12-01)

Omega-3 fatty acids may help improve treatment and quality of life in cancer patients
Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom. (2015-07-28)

Afatinib shows clinical benefit for lung cancer patients with brain metastases
Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI) afatinib compared to standard platinum doublet chemotherapy. (2016-01-25)

Selected gene mRNA expression is not predictive of improved overall survival
)-- A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-30)

Page 2 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.